Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (20635)	5/12/1998 11:20:00 PM
From: Andrew H	Respond to of 32384

>>Yes, but....... When the FDA put ONTAK on the "fast track", did they already have a feeling for it's effectiveness? In other words, even if ONTAK is on the "fast track", if the FDA didn't put much time into looking at the clinical results, before making that decision, then the probability of FDA approval is lower.<< I don't think the FDA spends much time evaluating the drug for effectiveness BEFORE granting fast track status. Once the status is granted, they simply perform their normal evaluation process faster than with non-fast track drugs. I don't think the probablility of approval is affected by the status. At least that's the way it ought to work in theory.